Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II, Open-Label, Uncontrolled, Dose-Escalation Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer

NCT01284920 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT01284920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01284920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II, Open-Label, Uncontrolled, Dose-Escalation Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer
Lead sponsor
Astellas Pharma Inc
Phase
Phase 1/2
Overall status
Completed
Start date
November 2, 2010
Completion date
July 2, 2014
Enrollment
47 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

castration resistant prostate cancer (crpc), prostate cancer, prostate neoplasms